Modulation of cellular localization of cyclin c
US-2016367630-A1 · Dec 22, 2016 · US
Compounds for enhancing p21 expression and methods of use thereof
US9029322B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9029322-B2 |
| Application number | US-66309108-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 5, 2008 |
| Priority date | Jun 5, 2007 |
| Publication date | May 12, 2015 |
| Grant date | May 12, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method for identifying a drug candidate for enhancing expression of p21cip1/waf1 in a human patient suffering from a medical condition that can be treated by enhancing expression of p21Cφ1/waf1. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21cip1/waf1 promoter operationally ligated to a reporter domain; (b) exposing the cell line to a compound; and (c) identifying a compound that induces expression of the reporter domain. The compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cip1/waf1.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for enhancing expression of p21 cip1/waf1 in a human patient suffering from a medical condition that can be treated by enhancing expression of p21 cip1/waf1 , the method comprising administering to the patient an effective amount of a compound selected from a group consisting of dihydrocelastrol, colistimethate sodium, lycorine, diphenylurea and chloroquine diphosphate, wherein expression of p21 cip1/waf1 is enhanced in the patient suffering from a…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Physics · mapped topic
- C07K14/4738Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9029322B2 cover?
- The present invention relates to a method for identifying a drug candidate for enhancing expression of p21cip1/waf1 in a human patient suffering from a medical condition that can be treated by enhancing expression of p21Cφ1/waf1. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21cip1/waf1 promoter operationally ligated to a reporter domain; (b)…
- Who is the assignee on this patent?
- Ratan Rajiv R, Langley Brett C, Ko Brian S, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/4738. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).